LyfeMD Inc.

LyfeMD’s digital platform provides evidence-based solutions to help manage life-altering chronic digestive diseases affecting 36% of the North American population. The platform is sold using a subscription model to pharmaceutical companies and pharmacies. Developed by gastroenterologists and dietitians, LyfeMD offers p

LyfeMD Inc. operates in prime.

Profile

LyfeMD’s digital platform provides evidence-based solutions to help manage life-altering chronic digestive diseases affecting 36% of the North American population. The platform is sold using a subscription model to pharmaceutical companies and pharmacies. Developed by gastroenterologists and dietitians, LyfeMD offers proprietary lifestyle therapy programs combined with coaching and health professional support to patients in Canada […]

LyfeMD Inc. is positioned in prime, a segment that rewards a clear, focused offering.

Its current recorded stage is Creative Destruction Lab alumni company.

Website: lyfemd.com